FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patientsPRNewsWire • 08/24/26
Louisiana Jury Issues $10 Million Verdict in Talc-Related Mesothelioma Case Against Johnson & JohnsonBusiness Wire • 08/24/26
J&J's Strong Pipeline Momentum Offers Multiple Growth Catalysts AheadZacks Investment Research • 08/24/26
Johnson & Johnson: Buy IMAAVY Label Expansion First And Continued CAPLYTA Sales PushSeeking Alpha • 08/23/26
Johnson & Johnson Wins FDA 510(k) Clearance for MONARCH QUEST 3 UpdateZacks Investment Research • 08/21/26
Johnson & Johnson (JNJ) Registers a Bigger Fall Than the Market: Important Facts to NoteZacks Investment Research • 08/20/26
Johnson & Johnson Just Sent Shareholders an Important 11-Word Message About Its FutureThe Motley Fool • 08/20/26
Why Bristol Myers, Johnson & Johnson and More Are Watching Seaport After IPO24/7 Wall Street • 08/20/26